| KMDA |
Kamada Ltd. |
72%
|
Reciprocal relationship from KMDA graph: tici S.p.A, Bio Products Laboratories (“BPL”) and Valneva SE, which are sold in our Distribution segment, together represented approximately 8%, 18% and 20% o… |
| SNYNF |
Sanofi |
72%
|
Reciprocal relationship from SNYNF graph: Reciprocal relationship from VALN graph: Reciprocal relationship from SNYNF graph: Reciprocal relationship from VALN graph: Reciprocal relationship from SNYN… |
| SNYNF |
Sanofi |
72%
|
en and Kaketsuken (Japan), both with inactivated vero-cell based vaccines, Chengdu (China and GAVI/UNICEF markets) with a live-attenuated vaccine, and Sanofi’s live-attenuated chimeric vaccine, IMOJE… |
| ALL-WALES-MEDICINES-STRATEGY-GROUP |
ALL-WALES-MEDICINES-STRATEGY-GROUP |
62%
|
her things, knowingly presenting, or causing to be presented, false, fictitious, or fraudulent claims for payment of federal funds, and knowingly making, using, or causing to be made or used a false … |
| BAYER-AG |
BAYER-AG |
62%
|
tates, Canada, the United Kingdom, Sweden, France, Austria, Norway, Denmark, Finland, Belgium, and the Netherlands. We commercialize our own and third-party vaccine brands to both private and governm… |
| BERLIN-CHEMIE-AG |
BERLIN-CHEMIE-AG |
62%
|
tates, Canada, the United Kingdom, Sweden, France, Austria, Norway, Denmark, Finland, Belgium, and the Netherlands. We commercialize our own and third-party vaccine brands to both private and governm… |
| BOEHRINGER-INGELHEIM-INTERNATIONAL-GMBH |
BOEHRINGER-INGELHEIM-INTERNATIONAL-GMBH |
62%
|
tates, Canada, the United Kingdom, Sweden, France, Austria, Norway, Denmark, Finland, Belgium, and the Netherlands. We commercialize our own and third-party vaccine brands to both private and governm… |
| CAPITAL-RESOURCES |
CAPITAL-RESOURCES |
62%
|
ber of minor agreements with various conditions (interest rates) and terms (maturities). Refund Liabilities 111 As of December 31, 2025, the carrying amount of refund liabilities was €17.5 million. O… |
| CRS |
Carpenter Technology Corporation |
62%
|
Reciprocal relationship from CRS graph: Reciprocal relationship from VALN graph: Reciprocal relationship from CRS graph: Reciprocal relationship from VALN graph: Reciprocal relationship from CRS grap… |
| CRUCELL-SWEDEN-AB-BERLIN-CHEMIE-AG |
CRUCELL-SWEDEN-AB-BERLIN-CHEMIE-AG |
62%
|
tates, Canada, the United Kingdom, Sweden, France, Austria, Norway, Denmark, Finland, Belgium, and the Netherlands. We commercialize our own and third-party vaccine brands to both private and governm… |
| GLAXOSMITHKLINE-BIOLOGICS-SA-GLAXOSMITHKLINE-GMB |
GLAXOSMITHKLINE-BIOLOGICS-SA-GLAXOSMITHKLINE-GMB |
62%
|
tates, Canada, the United Kingdom, Sweden, France, Austria, Norway, Denmark, Finland, Belgium, and the Netherlands. We commercialize our own and third-party vaccine brands to both private and governm… |
| INTERCELL-AG |
INTERCELL-AG |
62%
|
materials for which we rely on a single supplier could adversely affect our ability to manufacture our products and significantly raise our cost of production. We have not qualified secondary sources… |
| LIMMATECH-BIOLOGICS-AG |
LIMMATECH-BIOLOGICS-AG |
62%
|
artnership with LimmaTech Biologics AG, we are currently developing the world’s most clinically advanced tetravalent Shigella vaccine candidate (Phase 2). Our candidate includes the four most prevale… |
| UK-CORPORATION |
UK-CORPORATION |
62%
|
fording residents with certain rights concerning their personal data. As applicable, such rights may include the right to access, correct, or delete certain personal data, and to opt-out of certain d… |
| VALNEVA-AUSTRIA-GMBH |
VALNEVA-AUSTRIA-GMBH |
62%
|
estones, of which $ 3.0 million was paid in April 2024. The refundable consideration is accounted for as a loan and measured in accordance with IFRS 9 (see Note 5.24). The difference between the proc… |
| VALNEVA-SCOTLAND-LTD |
VALNEVA-SCOTLAND-LTD |
62%
|
her things, knowingly presenting, or causing to be presented, false, fictitious, or fraudulent claims for payment of federal funds, and knowingly making, using, or causing to be made or used a false … |
| VALNEVA-UK-LTD |
VALNEVA-UK-LTD |
62%
|
her things, knowingly presenting, or causing to be presented, false, fictitious, or fraudulent claims for payment of federal funds, and knowingly making, using, or causing to be made or used a false … |
| VALNEVA-USA-INC |
VALNEVA-USA-INC |
62%
|
estones, of which $ 3.0 million was paid in April 2024. The refundable consideration is accounted for as a loan and measured in accordance with IFRS 9 (see Note 5.24). The difference between the proc… |
| VBC3-ERRICHTUNGS-GMBH |
VBC3-ERRICHTUNGS-GMBH |
62%
|
her things, knowingly presenting, or causing to be presented, false, fictitious, or fraudulent claims for payment of federal funds, and knowingly making, using, or causing to be made or used a false … |
| VBI-VACCINES-INC |
VBI-VACCINES-INC |
62%
|
tates, Canada, the United Kingdom, Sweden, France, Austria, Norway, Denmark, Finland, Belgium, and the Netherlands. We commercialize our own and third-party vaccine brands to both private and governm… |
